Search Results - "Mauro, Michael"

Lifelong TKI therapy: how to manage cardiovascular and other risks by Mauro, Michael J

“…Beginning with imatinib and now spanning 6 oral, highly active, and mostly safe agents, the development of specific targeted therapy for patients with chronic…”
Get full text

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial by Cortes, Jorge E, Gambacorti-Passerini, Carlo, Deininger, Michael W, Mauro, Michael J, Chuah, Charles, Kim, Dong-Wook, Dyagil, Irina, Glushko, Nataliia, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Reilly, Laurence, Jeynes-Ellis, Allison, Leip, Eric, Bardy-Bouxin, Nathalie, Hochhaus, Andreas, Brümmendorf, Tim H

“…Purpose Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) resistant…”
Get full text

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs by Réa, Delphine, Mauro, Michael J., Boquimpani, Carla, Minami, Yosuke, Lomaia, Elza, Voloshin, Sergey, Turkina, Anna, Kim, Dong-Wook, Apperley, Jane F., Abdo, Andre, Fogliatto, Laura Maria, Kim, Dennis Dong Hwan, le Coutre, Philipp, Saussele, Susanne, Annunziata, Mario, Hughes, Timothy P., Chaudhri, Naeem, Sasaki, Koji, Chee, Lynette, García-Gutiérrez, Valentin, Cortes, Jorge E., Aimone, Paola, Allepuz, Alex, Quenet, Sara, Bédoucha, Véronique, Hochhaus, Andreas

“…Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing…”
Get full text

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial by Cortes, Jorge, Apperley, Jane, Lomaia, Elza, Moiraghi, Beatriz, Undurraga Sutton, Maria, Pavlovsky, Carolina, Chuah, Charles, Sacha, Tomasz, Lipton, Jeffrey H., Schiffer, Charles A., McCloskey, James, Hochhaus, Andreas, Rousselot, Philippe, Rosti, Gianantonio, de Lavallade, Hugues, Turkina, Anna, Rojas, Christine, Arthur, Christopher Kevin, Maness, Lori, Talpaz, Moshe, Mauro, Michael, Hall, Tracey, Lu, Vickie, Srivastava, Shouryadeep, Deininger, Michael

“…In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that included patients with chronic-phase chronic myeloid leukemia (CP-CML)…”
Get full text

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis by Gotlib, Jason, Kluin-Nelemans, Hanneke C, George, Tracy I, Akin, Cem, Sotlar, Karl, Hermine, Olivier, Awan, Farrukh T, Hexner, Elizabeth, Mauro, Michael J, Sternberg, David W, Villeneuve, Matthieu, Huntsman Labed, Alice, Stanek, Eric J, Hartmann, Karin, Horny, Hans-Peter, Valent, Peter, Reiter, Andreas

“…Midostaurin is a multikinase inhibitor that includes mutant and nonmutant KIT D816V as a target. Its use in patients with advanced systemic mastocytosis,…”
Get full text

Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia by Mauro, Michael J

“…PURPOSE OF REVIEWThe purpose of this review is to summarize treatment expectations and response milestones, to conceptualize the approach to defining…”
Get full text

Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care by Manouchehri, Ali, Kanu, Elishama, Mauro, Michael J., Aday, Aaron W., Lindner, Jonathan R., Moslehi, Javid

“…Targeted oncology therapies have revolutionized cancer treatment over the last decade and have resulted in improved prognosis for many patients. This advance…”
Get full text

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial by Brümmendorf, Tim H., Cortes, Jorge E., Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E., le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H., Rousselot, Philippe, Mauro, Michael J., Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea, Deininger, Michael W.

“…This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase…”
Get full text

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias by Cortes, Jorge E, Kantarjian, Hagop, Shah, Neil P, Bixby, Dale, Mauro, Michael J, Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I, Rivera, Victor M, Clackson, Tim, Turner, Christopher D, Haluska, Frank G, Druker, Brian J, Deininger, Michael W.N, Talpaz, Moshe

“…Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In…”
Get full text

Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes) by Mauro, Michael J.

“…Optimal outcomes with chronic myeloid leukemia treatment may not be attainable for those without health insurance or with Medicaid. Running the marathon…”
Get full text

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia by Branford, Susan, Kim, Dennis Dong Hwan, Apperley, Jane F., Eide, Christopher A., Mustjoki, Satu, Ong, S. Tiong, Nteliopoulos, Georgios, Ernst, Thomas, Chuah, Charles, Gambacorti-Passerini, Carlo, Mauro, Michael J., Druker, Brian J., Kim, Dong-Wook, Mahon, Francois-Xavier, Cortes, Jorge, Radich, Jerry P., Hochhaus, Andreas, Hughes, Timothy P.

“…Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention…”
Get full text

Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy by Barber, Mary C, Mauro, Michael J, Moslehi, Javid

“…Cardiovascular (CV) health has emerged as an important consideration in patients with chronic myeloid leukemia (CML) because of improved prognosis. Indeed, the…”
Get full text

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL by Hochhaus, Andreas, Réa, Delphine, Boquimpani, Carla, Minami, Yosuke, Cortes, Jorge E., Hughes, Timothy P., Apperley, Jane F., Lomaia, Elza, Voloshin, Sergey, Turkina, Anna, Kim, Dong-Wook, Abdo, Andre, Fogliatto, Laura Maria, le Coutre, Philipp, Sasaki, Koji, Kim, Dennis Dong Hwan, Saussele, Susanne, Annunziata, Mario, Chaudhri, Naeem, Chee, Lynette, García-Gutiérrez, Valentin, Kapoor, Shruti, Allepuz, Alex, Quenet, Sara, Bédoucha, Véronique, Mauro, Michael J.

“…Asciminib, the first BCR::ABL1 inhibitor that S pecifically T argets the A BL M yristoyl P ocket (STAMP), is approved worldwide for the treatment of adults…”
Get full text

Asciminib in Relapsed Chronic Myeloid Leukemia. Reply by Mauro, Michael J, Hughes, Timothy P

Get full text

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study by Shah, Neil P., García-Gutiérrez, Valentín, Jiménez-Velasco, Antonio, Larson, Sarah, Saussele, Susanne, Rea, Delphine, Mahon, François-Xavier, Levy, Moshe Yair, Gómez-Casares, María Teresa, Pane, Fabrizio, Nicolini, Franck-Emmanuel, Mauro, Michael J., Sy, Oumar, Martin-Regueira, Patricia, Lipton, Jeffrey H.

“…Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is considered a feasible option, especially with the ability…”
Get full text

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib by Shah, Neil P., Wallis, Nicola, Farber, Harrison W., Mauro, Michael J., Wolf, Robert A., Mattei, Daniele, Guha, Mausumee, Rea, Delphine, Peacock, Andrew

“…The prognosis of most leukemia patients treated with BCR‐ABL tyrosine kinase inhibitors (TKIs) is favorable, and a more precise understanding of serious and…”
Get full text

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis by Hartmann, Karin, Gotlib, Jason, Akin, Cem, Hermine, Olivier, Awan, Farrukh T., Hexner, Elizabeth, Mauro, Michael J., Menssen, Hans D., Redhu, Suman, Knoll, Stefanie, Sotlar, Karl, George, Tracy I., Horny, Hans-Peter, Valent, Peter, Reiter, Andreas, Kluin-Nelemans, Hanneke C.

“…Advanced systemic mastocytosis (advSM) is characterized by presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in…”
Get full text

A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer by Tavakkoli, Montreh, Wilkins, Cy R, Mones, Jodi V, Mauro, Michael J

“…Leukocytosis is a common feature of malignancies. While controversial, there appears to be an association between the degree of tumor-related leukocytosis and…”
Get full text

Can any patients with chronic myeloid leukemia outside of a clinical trial have their tyrosine kinase inhibitor discontinued? by Mauro, Michael J

“…PURPOSE OF REVIEWThis article critically appraises the state of treatment-free remission as a strategy for patients with chronic myeloid leukemia (CML) in deep…”
Get full text

Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition by Yao, JinJuan, Xu, Lianrong, Aypar, Umut, Meyerson, Howard J, Londono, Dory, Gao, Qi, Baik, Jeeyeon, Dietz, James, Benayed, Ryma, Sigler, Allison, Yabe, Mariko, Dogan, Ahmet, Arcila, Maria E, Roshal, Mikhail, Zhang, Yanming, Mauro, Michael J, Xiao, Wenbin

Get full text